Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR Delaware (State or other jurisdiction of incorporation or organization) 1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania (Address of principal executive offices) (484) 320-2930 (Registrant's telephone number, including area code) Securities registered ...

TELA Bio, Inc. (NASDAQ:TELA) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Stuart Henderson - VP, Corporate Development and IR Tony Koblish - President and CEO Nora Brennan - CFO Conference Call Participants Raj Denhoy - Jefferies Matthew O'Brien - Piper Sandler Kyle Rose - Canaccord Dave Turkaly - JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio's Third Quarter 2020 Earnings Conference Call. At this time, all participants are in ...

TELA Bio: Advancing Soft Tissue Reconstruction August 2020 Nasdaq: TELA 1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assumed future results of operations, business strategies, development plans, regulatory activities, market opportunity competitive po ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37526 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdict ...

TELA Bio, Inc. (NASDAQ:TELA) Q2 2020 Earnings Conference Call August 12, 2020 4:30 PM ET Company Participants Stuart Henderson - Vice President, Corporate Development & Investor Relations Tony Koblish - President & Chief Executive Officer Nora Brennan - Chief Financial Officer. Conference Call Participants Raj Denhoy - Jefferies Matthew O'Brien - Piper Sandler Kyle Rose - Canaccord Dave Turkaly - JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio's Second Quarter 2020 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37526 Securities registered pursuant to Section 12(b) of the Act: 45-5320061 (I.R.S. Employer Identification ...

TELA Bio, Inc. (NASDAQ:TELA) Q1 2020 Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants Stuart Henderson - VP, Corporate Development and Investor Relations Antony Koblish - President and CEO Nora Brennan - CFO Conference Call Participants Raj Denhoy - Jefferies Matthew O'Brien - Piper Sandler Kyle Rose - Canaccord Dave Turkaly - JMP Securities Operator Good afternoon, ladies and gentlemen, and welcome to the TELA Bio's First Quarter 2020 Earnings Conference Call. At this time all particip ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37526 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction ...

TELA Bio, Inc. (NASDAQ:TELA) Q4 2019 Earnings Conference Call March 27, 2020 8:00 AM ET Company Participants Stuart Henderson - Vice President, Corporate Development and Investor Relations Antony Koblish - Co-founder, President, Chief Executive Officer Nora Brennan - Chief Financial Officer Conference Call Participants Raj Denhoy - Jefferies & Company, Inc. Matthew O'Brien - Piper Sandler Kyle Rose - Canaccord Genuity Inc. David Turkaly - JMP Securities Operator Good morning, ladies and gentlemen, and welco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37526 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other juri ...